Catalyst Pharmaceutical (CPRX) CPP-115 Suppresses Infantile Spasms in the rat Multiple-hit Model

Welcome to CRWENewswire, Stocks to Watch. I am Shalika Jayasekera. Catalyst Pharmaceutical Partners Inc - CPRX - reported that a poster presentation about the company’s next-generation GABA aminotransferase inhibitor, CPP-115, will be made on Dec. 3rd, 2011 at the American Epilepsy Society’s 65th Annual Meeting. The poster describes a study conclusions, demonstrating that CPP-115 suppresses infantile spasms in the rat multiple-hit model. Infantile spasm is a rare seizure disorder of infancy and early childhood. Characteristic features of Infantile spasms include myoclonic seizures, hypsarrhythmia (abnormal, chaotic electroencephalogram), and mental retardation. Catalyst Pharmaceutical is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy. For CRWE Newswire, Stocks to watch, I’m Shalika Jayasekera